スニチニブリンゴ酸塩の世界市場

スニチニブリンゴ酸塩の世界市場は2030年までに2億800万米ドルに達する見込み

2023年に1億910万米ドルと推定されるスニチニブリンゴ酸塩の世界市場は、2030年には2億800万米ドルに達し、分析期間2023-2030年のCAGRは9.7%で成長すると予測されます。本レポートで分析したセグメントの1つである「純度99％超スニチニブリンゴ酸塩」は、CAGR 10.6％を記録し、分析期間終了時には1億900万米ドルに達すると予測されます。純度98%以上のスニチニブリンゴ酸塩セグメントの成長率は、分析期間中CAGR 9.3%と推定されます。

米国市場は3,190万米ドルと推定、中国はCAGR 8.7％で成長予測

米国のスニチニブリンゴ酸塩市場は、2023年に3,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023年から2030年にかけてCAGR 8.7%で推移し、2030年には予測市場規模3,530万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.6％と7.7％と予測されています。欧州では、ドイツがCAGR約7.5%で成長すると予測されています。

世界のスニチニブリンゴ酸塩市場- 主要動向と促進要因のまとめ

スニチニブリンゴ酸塩ががん標的治療薬のキープレイヤーである理由とは？

経口マルチキナーゼ阻害薬であるスニチニブリンゴ酸塩は、腎細胞がん（RCC）や消化管間質腫瘍（GIST）など、さまざまな種類のがんの治療において極めて重要な役割を果たしています。スニチニブは、標的治療薬の重要な薬剤の1つとして、血管新生、増殖、転移など腫瘍の増殖に関与する複数の経路を阻害することにより作用します。スニチニブは、進行した腎臓がんやその他の悪性腫瘍の治療に有効であるとしてFDAに承認されており、従来の化学療法では効果が不十分な患者に命綱を提供しています。血管内皮増殖因子（VEGFR）および血小板由来増殖因子受容体（PDGFR）を阻害するその能力は、スニチニブを標的腫瘍学市場の要として位置づけています。がん罹患率の上昇と個別化医療に対する需要の高まりが、スニチニブのがん領域での採用を後押ししています。

スニチニブリンゴ酸塩の将来を形作るイノベーションとは？

最近の精密医療の進歩は、希少がんや治療困難ながんの治療においてスニチニブリンゴ酸塩に新たな道を開いています。スニチニブと他の免疫療法を組み合わせて治療効果を高め、薬剤耐性を克服する研究が注目されています。また、バイオマーカーの開発により、スニチニブ治療が最も有効な患者をがん専門医が特定し、治療成績が向上しています。現在進行中の臨床試験では、チェックポイント阻害剤との併用によるスニチニブの応用が検討されており、患者の生存率延長において有望な結果が得られています。しかし、薬剤耐性や高血圧や疲労などの副作用といった課題が、スニチニブの有効性を損なうことなく安全性プロファイルを改善するためのさらなる調査に拍車をかけています。

どの市場セグメンテーションがスニチニブリンゴ酸塩をリードしているか？

スニチニブは腎細胞がん（RCC）の進行・転移型に対する第一選択治療薬であるため、最大のセグメントは依然として腎細胞がん（RCC）です。スニチニブは、消化管間質腫瘍（GIST）治療市場でも、特にイマチニブに反応しない患者の間で人気を集めています。地域別では、がんの罹患率の高さ、有利な償還政策、強力な医薬品インフラにより、北米が最大の市場シェアを占めています。欧州は、がん治療と臨床研究の進歩に牽引され、僅差で続いています。一方、アジア太平洋の新興市場は、がん罹患率の増加やヘルスケアへのアクセスの改善によって需要が急増しています。

スニチニブリンゴ酸塩市場の成長の原動力は？

スニチニブリンゴ酸塩市場の成長は、腎細胞がんや消化管間質腫瘍の罹患率の上昇、標的療法の採用増加、プレシジョン・オンコロジーの進歩など、いくつかの要因によってもたらされます。がん研究への投資拡大と併用療法の開発は、特に転移性がんにおいて薬剤の適用を拡大しています。さらに、希少がんに対するスニチニブの承認拡大と新興市場での臨床試験の増加が、市場浸透を後押ししています。新興国市場におけるヘルスケア支出の増加とがん治療へのアクセスの向上は、市場の拡大をさらに加速させています。

調査対象企業の例（注目の44社）

• Active Biotech AB
• Astellas Pharma, Inc.
• Bristol-Myers Squibb Company
• Changzhou Highassay Chemical Co., Ltd
• Dendreon Pharmaceuticals LLC
• Ferring Pharmaceuticals Inc
• Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
• Medichem, S.A.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Sunitinib Malate Market to Reach US$208.0 Million by 2030

The global market for Sunitinib Malate estimated at US$109.1 Million in the year 2023, is expected to reach US$208.0 Million by 2030, growing at a CAGR of 9.7% over the analysis period 2023-2030. Above 99% Purity Sunitinib Malate, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$109.0 Million by the end of the analysis period. Growth in the Above 98% Purity Sunitinib Malate segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.9 Million While China is Forecast to Grow at 8.7% CAGR

The Sunitinib Malate market in the U.S. is estimated at US$31.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$35.3 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Sunitinib Malate Market - Key Trends and Drivers Summarized

Why Is Sunitinib Malate a Key Player in Targeted Cancer Therapies?

Sunitinib Malate, an oral multi-kinase inhibitor, plays a pivotal role in the treatment of various types of cancer, including renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). As one of the key drugs in targeted therapy, Sunitinib works by inhibiting multiple pathways involved in tumor growth, including angiogenesis, proliferation, and metastasis. Approved by the FDA for its efficacy in treating advanced kidney cancer and other malignancies, Sunitinib offers a lifeline for patients who do not respond well to conventional chemotherapy. Its ability to block vascular endothelial growth factors (VEGFR) and platelet-derived growth factor receptors (PDGFR) has positioned it as a cornerstone in the targeted oncology market. The rising incidence of cancer and the growing demand for personalized medicine have driven the adoption of Sunitinib in oncology.

What Are the Innovations Shaping the Future of Sunitinib Malate?

Recent advancements in precision medicine have opened up new avenues for Sunitinib Malate in the treatment of rare and hard-to-treat cancers. Research is focusing on combining Sunitinib with other immunotherapies to enhance treatment efficacy and overcome drug resistance. Additionally, the development of biomarkers is helping oncologists identify patients who would benefit the most from Sunitinib therapy, thus improving treatment outcomes. Ongoing clinical trials are exploring its applications in combination with checkpoint inhibitors, showing promising results in extending patient survival rates. However, challenges such as drug resistance and side effects like hypertension and fatigue have spurred further research into improving the safety profile of Sunitinib without compromising its effectiveness.

Which Market Segments Are Leading for Sunitinib Malate?

The largest segment remains renal cell carcinoma (RCC), as Sunitinib is a first-line treatment for advanced and metastatic forms of this cancer. The drug is also gaining traction in the gastrointestinal stromal tumor (GIST) treatment market, particularly among patients who do not respond to imatinib. Regionally, North America holds the largest market share due to high cancer prevalence, favorable reimbursement policies, and a strong pharmaceutical infrastructure. Europe follows closely, driven by advancements in cancer treatment and clinical research. Meanwhile, emerging markets in Asia-Pacific are witnessing rapid growth in demand, fueled by increasing cancer rates and improving healthcare access.

What Is Driving Growth in the Sunitinib Malate Market?

The growth in the Sunitinib Malate market is driven by several factors, including the rising incidence of renal cell carcinoma and gastrointestinal stromal tumors, increasing adoption of targeted therapies, and advancements in precision oncology. Growing investments in cancer research and the development of combination therapies are expanding the drug’s application, particularly in metastatic cancers. Additionally, the expanding approval of Sunitinib for rare cancer indications, along with the growth of clinical trials in emerging markets, is boosting market penetration. The increasing healthcare expenditure and enhanced access to oncology treatments in developing regions are further accelerating market expansion.

Select Competitors (Total 44 Featured) -

• Active Biotech AB
• Astellas Pharma, Inc.
• Bristol-Myers Squibb Company
• Changzhou Highassay Chemical Co., Ltd
• Dendreon Pharmaceuticals LLC
• Ferring Pharmaceuticals Inc
• Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
• Medichem, S.A.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Sunitinib Malate - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cancer Drives Demand for Sunitinib Malate in Oncology Treatments
  • Expansion of Targeted Therapies in Cancer Treatment Spurs Growth in Sunitinib Malate Market
  • Increased FDA Approvals for New Cancer Indications Expands Addressable Market Opportunity
  • Advancements in Precision Medicine Strengthen the Business Case for Sunitinib Malate
  • Rising Demand for Personalized Cancer Treatments Generates Market Growth
  • Emerging Clinical Trials for Combination Therapies Propels Market Competitiveness
  • Challenges Related to Drug Resistance in Cancer Treatments Create Opportunities for New Developments
  • Rising Investments in Cancer Research Accelerates Demand for Targeted Therapies
  • Increasing Focus on Orphan Drug Development Throws Spotlight on Sunitinib Malate
  • Growing Application in Metastatic Cancer Treatments Sustains Market Growth
  • Emergence of Biosimilars in Oncology Pharmaceuticals Creates Competitive Pressures
  • Growing Geriatric Population with High Cancer Susceptibility Propels Demand for Sunitinib Malate
  • Rising Healthcare Expenditure in Emerging Economies Boosts Market Penetration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Sunitinib Malate Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Above 99% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for Above 99% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Above 98% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Above 98% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Above 97% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Above 97% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Pancreatic Neuroendocrine Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 11: World 7-Year Perspective for Pancreatic Neuroendocrine Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 13: World 7-Year Perspective for Gastrointestinal Stromal Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Kidney Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 15: World 7-Year Perspective for Kidney Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 16: USA Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 17: USA 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 18: USA Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 19: USA 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Canada 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• JAPAN
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 24: Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Japan 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• CHINA
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 28: China Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 29: China 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 30: China Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 31: China 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• EUROPE
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe 7-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Europe 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Europe 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• FRANCE
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 40: France Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 41: France 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• GERMANY
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 42: Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 43: Germany 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Germany 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• ITALY
  • TABLE 46: Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Italy 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Italy 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• UNITED KINGDOM
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: UK 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 52: UK Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 53: UK 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 55: Rest of Europe 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of Europe 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• ASIA-PACIFIC
  • Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Asia-Pacific 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Asia-Pacific 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Rest of World 7-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2024 & 2030
  • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Rest of World 7-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2024 & 2030

IV. COMPETITION